Biomarin Pharmaceutical Inc operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biomarin Pharmaceutical Inc with three other
companies in this sector in the United States:
sales of $985.08 million
of which 94%
was Prescription Pharmaceuticals),
of which 100%
was Medical Technologies), and
Impax Laboratories, Inc.
of which 83%
was Impax Generics).
Biomarin Pharmaceutical Inc reported sales of $889.90 million
December of 2015.
increase of 18.5%
versus 2014, when the company's sales were $751.04 million.
Sales at Biomarin Pharmaceutical Inc have increased during each of the previous five years
(and since 2010, sales have increased a total of 139%).
Sales of Vimizim saw an increase
that was more than double the company's growth rate: sales were up
195.1% in 2015, from
$77.32 million to $228.15 million.
Not all segments of Biomarin Pharmaceutical Inc experienced an increase in sales in 2015:
sales of Firdapse fell 11.1% to $16.04 million.
(However, this segment's sales were only a very small portion of the company's overall sales).
Biomarin Pharmaceutical Inc also experienced decreases in sales in
Naglazyme (down 9.4% to $303.09 million)
Aldurazyme (down 7.3% to $97.91 million)